Literature DB >> 110947

A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thio-tepa.

B N Nocks, P T Nieh, G R Prout.   

Abstract

Herein is reported further results of a prospective clinical investigation to determine the effect of weekly intravesical bladder instillation of thio-tepa in the treatment of superficial bladder cancer. Patients with superficial bladder carcinoma were treated according to 2 protocols. The first protocol consisted of patients with persistent tumor who were treated with weekly thio-tepa for 8 weeks. Of the 33 patients 18 responded to this therapy, and they and 24 other patients who had been rendered free of tumor by transurethral resection alone were assigned to the second protocol in which patients either were treated with monthly instillations of thio-tepa or they were observed every 3 months in a prescribed fashion. Monthly thio-tepa instillations had no significant effect in lowering the recurrence rate in either group. However, in the patients who had responded to weekly thio-tepa benefit was noted in terms of 1) fewer recurrences, with 8 of 18 (44 per cent) previously pre-treated patients having a recurrence versus 19 of 24 patients (79 per cent) previously untreated, 2) delay in tumor recurrence with an interval free of tumor of 15.1 months in pre-treated patients versus 4.3 months in the untreated group and 3) diminished frequency of new tumors (0.33 recurrences yearly) in comparison to the untreated group (1.78 recurrences yearly). The remaining patients are free of tumors at 15.7 months average followup.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110947     DOI: 10.1016/s0022-5347(17)56236-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  Thiotepa versus Bacille Calmette-Guérin in Non-Muscle Invasive Bladder Cancer.

Authors:  Fatemeh Fallah; Mahdi Fallah; Raheleh Sadat Sajadi Nia
Journal:  Curr Urol       Date:  2012-12-21

2.  Anticancer drug sensitivity in vitro in the bladder cancer cell line, KK-47 and prophylactic use of carbazilquinone and urokinase in bladder cancer.

Authors:  H Hisazumi; T Uchibayashi; M Katoh; T Kobayashi; K Nakajima; K Naitoh; T Misaki; K Kuroda
Journal:  Urol Res       Date:  1981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.